Anaemia is one of the most significant factors that lead to deteriorated quality of life and limited therapeutic possibilities in cancer patients. When treating chronic anaemia associated with a neoplastic disease, one should consider RBC transfusion or the use of recombinant human erythropoiesis-stimulating agents (ESA).
InTRoduCTIon
Anaemia is one of the most significant factors that lead to deteriorated quality of life and limited therapeutic possibilities in cancer patients. Incidence of anaemia in cancer patients ranges from 40% in the case of solid tumours, chiefly lung cancer and gynaecological tumours, up to nearly 100% in hematologic malignancies [8] .
Anti-cancer treatment and cytokines induced by the chronic inflammatory process inhibit erythropoiesis by means of reducing erythropoietin production, amongst other mechanisms involved [1, 2] . Other factors that may trigger anaemia and affect its intensity include: congenital red cell structure and function abnormalities, malnutrition, iron, vitamin B 12 and folic acid deficiencies, elderly age, haemorrhages, hypersplenism, haemolysis, secondary bone marrow involvement, kidney diseases and radiotherapy [1, 2] . Additionally, mutations or therapy-induced inhibition of the intracellular c-kit domain may partially be to blame for reduced erythropoiesis. It is caused by a reduction in the c-kit-dependent phosphorylation and in the intracellular interaction between c-kit and the tyrosine kinase domain of the erythropoietin receptor [1] .
Physiological consequences of low haemoglobin levels are similar irrespectively of their origin, whereas their therapeutic management differs, depending on the degree of anaemia, intensity of the symptoms involved, and the patient's clinical situation, including the type of anti-cancer therapy applied, the goal of treatment, and presence of comorbidities.
Having eliminated causes of anaemia other than chronic disease-induced anaemia, one should consider a red cell concentrate transfusion or use of ESA. Transfusion of red cell concentrates is associated with risks such as hypervolemia, transmission of viral or bacterial infections, iron overload, and transfusion--related acute lung injury (TRALI), which is why clinicians have been greatly interested in using ESA.
ReComBInAnT eRyThRopoIeSIS-STImulATIng AgenTS
Erythropoietin (EPO) is a glycoprotein peptide hormone, secreted in the human body primarily by the kidneys (ca. 80% of EPO synthesis), and to a lesser degree by the liver. Based on a closed--loop feedback mechanism, hormone expression depends on tissue hypoxia, which stimulates renal cells to produce EPO. Once the erythrocyte count increases, and tissue oxygenation rises, hormone production drops. Erythropoietin is active upon binding with the specific transmembrane erythropoietin receptor (EpoR). Recombinant erythropoietin-stimulating agents behave just like the human erythropoietin protein.
There are 3 products available on the market: epoetin α, epoetin β and darbepoetin α. The first 2 are analogues of their human counterparts, while the third one differs from them in that it contains additional glycosylation sites, and thus has a longer half-life.
ESAs are indicated in the treatment of anaemia resulting from a chronic kidney disease, chemotherapy and some HIV treatment methods. They are also used in order to lower the number of blood transfusions during and after certain surgical procedures.
ClInICAl uSe of eSA -ConTRoveRSIeS
Before 2006, ESA use in anaemic patients undergoing anti-cancer treatment was considered safe and efficacious.
In 2003, a randomized controlled trial was carried out in 351 patients with head and neck tumours, whose baseline haemoglobin levels were below 12 g/l in women and below 13 g/l in male subjects. The patients received radiotherapy, and were randomized to the subcutaneous placebo arm (n = 171) or to the epoetin β arm (n = 180), administered 3 times a week, before and during irradiation. Progression-free survival and overall survival times were assessed. In the epoetin β group, overall survival time was shorter, amounting to 605 days as compared to 928 days in the placebo group (p = 0.02), and locoregional progression was faster by nearly 2 months (p = 0.007). However, those critical of the study design pointed out the high baseline haemoglobin levels at which patients were started on EPO [5] .
The unfavourable effect of ESA was also observed in a study of 2005, conducted by Leyland-Johnes et al. The impact of epoetin α on patient survival and quality of life was compared to placebo in female patients with metastatic breast cancer, undergoing first-line chemotherapy, with haemoglobin levels ranging from 12 to 14 g/dl. 12-month overall survival (OS) was the primary endpoint of the study, and it amounted to 70% in the epoetin α group, and 76% in the placebo arm (p = 0.01) [6] . In early 2007, The above findings indicate that in some tumours ESAs may play a role in tumour promotion [11] . Authors' contributions: Marta Frąckowiak: 70%; Tomasz Lewandowski: 30%.
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